Uterine Smooth Muscle S-Nitrosylproteome in Pregnancy

  1. Craig Ulrich,
  2. David R. Quillici,
  3. Kathleen Schegg,
  4. Rebekah Woolsey,
  5. Akira Nordmeier and
  6. Iain L. O. Buxton
  1. Department of Pharmacology, University of Nevada School of Medicine (C.U., A.N., I.L.O.B.), and Nevada Proteomics Center (D.R.Q., K.S., R.W.), University of Nevada, Reno, Nevada
  1. Address correspondence to:
    Professor Iain Buxton, Department of Pharmacology, University of Nevada School of Medicine, 1664 N. Virginia St., Reno, NV 89557. E-mail: ibuxton{at}medicine.nevada.edu

Abstract

The molecular mechanisms involved in uterine quiescence during gestation and those responsible for induction of labor are not completely known. Nitric oxide relaxes uterine smooth muscle in a manner disparate from that for other smooth muscles because global elevation of cGMP after activation of soluble guanylyl cyclase does not relax the muscle. S-Nitrosylation, the covalent addition of an nitric oxide (NO) group to a cysteine thiol is a likely mechanism to explain the ability of NO to relax myometrium. This work is the first to describe the myometrial S-nitrosylproteome in both pregnant and nonpregnant tissue states. Using the guinea pig model, we show that specific sets of proteins involved in contraction and relaxation are S-nitrosylated in laboring and nonlaboring muscle and that many of these proteins are uniquely S-nitrosylated in only one state of the tissue. In particular, we show that S-nitrosylation of the intermediate filament protein desmin is significantly increased (5.7-fold, p < 0.005) in pregnancy and that this increase cannot be attributed solely to the increase in protein expression (1.8-fold, p < 0.005) that accompanies pregnancy. Elucidation of the myometrial S-nitrosylproteome provides a list of mechanistically important proteins that can constitute the basis of hypotheses formed to explain the regulation of uterine contraction/relaxation.

Footnotes

  • This work was supported by the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development [Grant R01-HD053028]; National Institutes of Health National Center for Research Resources [Grant P20-RR016464]; and a Gates Grand Challenges Grant (to I.L.O.B.).

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    http://dx.doi.org/10.1124/mol.111.075804.

  • ABBREVIATIONS:

    USM
    uterine smooth muscle
    NO
    nitric oxide
    LY 83583
    6-anilino-5,8-quinolinedione
    NEM
    N-ethylmaleimide
    CHAPS
    3-(3-cholamidopropyl)dimethylammonio-1-propanesulfonate
    biotin-HPDP
    N-[6-(biotinamido)hexyl]-3′-(2′-pyridyldithio) propionamide
    GSNO
    S-nitroso-glutathione
    LC
    liquid chromatography
    MS/MS
    tandem mass spectrometry
    DIGE
    two-dimensional in-gel electrophoresis
    MS
    mass spectrometry
    MALDI
    matrix-assisted laser desorption ionization
    TOF/TOF
    tandem time of flight
    S/N
    signal/noise ratio
    SNO
    S-nitrosothiol
    MYLK
    myosin light chain kinase
    HSP27
    heat shock protein β-1
    IF
    intermediate filament.

  • Received September 16, 2011.
  • Accepted October 25, 2011.
| Table of Contents

This Article

  1. Molecular Pharmacology February 2012 vol. 81 no. 2 143-153
  1. All Versions of this Article:
    1. mol.111.075804v1
    2. 81/2/143 most recent

Classifications

Responses

  • ASPET Pharmacology Education Division